Midodrine in Hepatopulmonary Syndrome

Mayo Clinic10 enrolled

Overview

This proof-of-concept clinical trial will determine the safety and tolerability of midodrine in patients with hepatopulmonary syndrome (HPS). Exploratory endpoints will assess the effect of midodrine on oxygenation, intrapulmonary shunting and symptoms.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Hepatopulmonary Syndrome (HPS)

Interventions

MidodrineDRUG

Midodrine is an oral alpha-1 agonist that increases vascular tone. It is administered orally. The initial starting dose will be midodrine 5mg orally three times a day. After 7-10 days, patients will increase the dose to 10mg three times a day as tolerated if no adverse effects occur. Treatment duration will be 6 months.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Moderate to very severe hepatopulmonary syndrome, defined as the presence of all of the following: 1. Liver disease or portal hypertension 2. Intrapulmonary shunting on contrast-enhanced echocardiogram 3. Hypoxemia \[A-a gradient ≥15mmHg (or ≥20mmHg if age \>64) and PaO2\<80mmHg on arterial blood gas testing\] * Ability to provide informed consent * Ability to comply with study medication use and testing, in the opinion of the principal investigator or co-investigator Exclusion Criteria: * Vulnerable study population, including imprisoned individuals, non-English speaking patients * Participation in other investigational drug studies * Any of the following conditions: * Systolic blood pressure\>160mmHg or diastolic blood pressure \>100mmHg * Heart rate \<50bpm * Urinary retention at baseline * Left ventricular ejection fraction \<50% * Women who are pregnant, nursing, or who plan to become pregnant while in the trial * Women of child-bearing potential not willing or able to use highly effective methods of birth control

Locations (1)

Mayo Clinic in Rochester

Rochester, Minnesota, United States

Outcomes

Primary Outcomes

Safety and tolerability (adverse events (AEs))

Outcome will be defined by the incidence of adverse events (AEs) that occur during the study period. An adverse event is defined as any symptom, sign, illness or experience that develops or worsens in severity during the course of the study. Abnormal results of diagnostic procedures are considered to be AEs if the abnormality results in study withdrawal, is associated with a serious AE, is associated with clinical signs or symptoms, leads to additional treatment or further diagnostic tests or is considered by the investigator to be of clinical significance. Each adverse event will be further characterized by severity and relationship to the study drug. Adverse event are classified as serious if they are: fatal, life-threatening, require or prolongs hospital stay, lead to persistent or significant disability or incapacity or a congenital anomaly or birth defect.

Time frame: 6 months

Secondary Outcomes

Arterial Oxygenation

Describe the effect of midodrine on: • arterial oxygenation (PaO2 and A-a gradient )(mmHg)

Time frame: 3 months and 6 months

Diffusion capacity

Describe the effect of midodrine on: • percent predicted diffusion capacity for carbon monoxide (Range 0-100%)

Time frame: 3 months and 6 months

Cardiac output

Describe the effect of midodrine on cardiac output (L/min) as estimated by echocardiogram in patients with HPS.

Time frame: 3 months and 6 months

Intrapulmonary shunting

Describe the effect of midodrine on severity (mild, moderate or severe) of intrapulmonary shunting (as assessed by echocardiogram shunt study) in patients with HPS.

Time frame: 3 months and 6 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.